Biofire land NGDS

BioFire Defense, LLC announced that it had been awarded the Next Generation Diagnostic System (NGDS) Technology Development contract by the US Department of Defense (DoD) after 12 months of competitive prototyping

NGDS is a 8 year $240M biodefense program, managed by the Joint Program Executive Office’s Medical Countermeasure Systems (JPEO MCS) office. The NGDS program will expand BioFire’s FilmArray diagnostic menu by developing Biothreat test capabilities for use across all four branches of the DoD.

The NGDS program will develop and deliver the new standard of biowarfare detection to the US Department of Defense, replacing the current Joint Biologic Agent Identification and Diagnostic System (JBAIDS). With the dual role FilmArray platform, the DoD will be able to detect bioterror pathogens, as well as run the full suite of diagnostic test panels available for the system, including Respiratory and Blood Culture test panels. Other options in the contract include additional test panel development and platform hardening for improved ruggedness.

Tags: Detection, Threat, Identification, Contract, Defense, Warfare

Our Current Sponsors

  • Flir
  • BioFire Defense
  • Federal Resources
  • Cristanini
  • Airboss
  • Flir
  • Argon
  • 908 Devices
  • Avon
  • Battelle
  • Flir
  • Bruker
  • Bw Tek
  • CQC
  • Decon Seven Systems
  • Flir
  • DQE
  • Dxterity
  • Emergent Biosol
  • Endeavor Roborics
  • Flir
  • First Line Technology
  • Futurtech
  • Metrohm Raman
  • NBC sys
  • Flir
  • Proengin
  • Qinetiq
  • Tex Shield
  • Wl Gore
  • ADS, Inc.